- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 707KB)
Bimekizumab – March 2023
Bimekizumab: Injection 160 mg in 1 mL single use pre-filled syringe, Injection 160 mg in 1 mL single use pre-filled pen; Bimzelx®
Last updated
8 July 2026